RxSight to present at Stifel 2026 Virtual Ophthalmology Forum on May 26
RxSight, Inc., a company specializing in adjustable intraocular lenses for cataract surgery, will participate in the Stifel 2026 Virtual Ophthalmology Forum. The management team is scheduled for a fireside chat on May 26, 2026, at 10:00 a.m. Pacific Time. The event will be webcast live and archived on RxSight's investor relations website, offering investors insights into the company's vision correction technology and future outlook.
RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum
RxSight, Inc. announced its participation in the Stifel 2026 Virtual Ophthalmology Forum, where management will hold a fireside chat on May 26, 2026, at 10:00 a.m. Pacific Time. A webcast of the presentation will be available on the company's investor relations website. RxSight specializes in ophthalmic medical devices, specifically the Light Adjustable Lens system, which allows for post-surgery vision customization for cataract patients.
RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum
RxSight, Inc. announced its participation in the Stifel 2026 Virtual Ophthalmology Forum, where management will engage in a fireside chat on May 26, 2026, at 10:00 a.m. Pacific Time. The event's webcast will be accessible via the company's investor relations website. RxSight specializes in advanced ophthalmic medical devices, notably their Light Adjustable Lens system, which allows post-surgery customization of vision for cataract patients.
RxSight management to appear at Stifel 2026 virtual eye forum May 26
RxSight, Inc. (NASDAQ: RXST) announced its management will participate in a fireside chat at the Stifel 2026 Virtual Ophthalmology Forum on May 26, 2026, at 10:00 a.m. Pacific Time. A live and archived webcast will be available on the company's investor relations website. This event is part of RxSight's ongoing investor outreach, which has historically shown mixed reactions in stock price around similar conference appearances, earnings, and milestone announcements.
RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum
RxSight, Inc. announced its participation in the Stifel 2026 Virtual Ophthalmology Forum, where management will hold a fireside chat on May 26, 2026, at 10:00 a.m. Pacific Time. A webcast of the presentation will be available on the company’s investor relations website. RxSight specializes in ophthalmic medical devices, offering the RxSight Light Adjustable Lens system for customized vision after cataract surgery.
RxSight stock (US78419L1008): FDA-linked growth and execution stay in focus
RxSight (RXST) is a closely watched small-cap company in the US elective eye-care market, with its growth tied to the adoption and utilization of its Light Adjustable Lens platform for cataract surgery. The company's business model relies on placing capital equipment in ophthalmology practices and then generating recurring revenue from lens sales and procedures. RxSight's performance is sensitive to surgeon adoption, patient willingness to pay for premium lenses, and efficient execution in the US market.
RxSight stock (US78419L1008): FDA-backed growth story stays in focus
RxSight, a medical device company, is gaining investor attention for its Light Adjustable Lens platform used in cataract surgery. The company's business model relies on both capital equipment sales and recurring consumables, making it appealing to investors tracking medical technology growth. Key drivers for RxSight include physician adoption, procedure volumes, and market penetration, while risks involve slower-than-expected adoption, competitive pressures, and managing operating expenses.
Number of shareholders of RxSight, Inc. – NASDAQ:RXST
This article provides details on the number of shareholders for RxSight, Inc. (NASDAQ: RXST). It includes general market data and corporate information from TradingView, focusing on financial metrics and general company overview within the stock market context. The content is primarily a data placeholder rather than an in-depth analysis.
RXST: Stable Q1 results and ongoing commercial initiatives support sequential growth and global expansion
RxSight, Inc. (RXST) reported stable Q1 results that exceeded expectations, maintaining revenue guidance and demonstrating stable LAL sales. The company anticipates sequential growth driven by deeper practice engagement and international expansion, despite competitive headwinds factored into its outlook. This summary is based on the Bank of America Global Healthcare Conference 2026 audio transcript from May 13, 2026.
Artisan Partners reports 5.0% stake in RxSight (NASDAQ: RXST)
Artisan Partners and its affiliated entities have reported a 5.0% beneficial ownership stake in RxSight, Inc. (NASDAQ: RXST), holding 2,058,684 shares. This disclosure, made via a Schedule 13G/A filing on May 13, 2026, indicates a passive institutional investment rather than an active attempt to influence company control. The filing details shared voting power of 1,856,861 shares and shared dispositive power over all 2,058,684 shares.
RxSight, Inc. (NASDAQ:RXST) Q1 2026 Earnings Call Transcript
RxSight, Inc. (NASDAQ: RXST) reported its Q1 2026 earnings, with sales of $30.9 million, an 18% decline reflecting lower LDD unit volumes, though LAL unit volumes remained consistent with the prior year. The company is seeing stabilization in LAL utilization and positive early signs from customer reengagement programs, influencing its reaffirmed full-year revenue guidance of $120 million to $135 million. RxSight continues its measured international expansion and is investing in global commercial organization and R&D to drive long-term growth.
RxSight (RXST) Loss Widening To US$46.6 Million Tests Bullish Growth Narratives
RxSight (RXST) reported a widened net loss of US$15.9 million in Q1 2026, with trailing twelve-month losses reaching US$46.6 million. Despite 7.2% annual revenue growth, the company remains unprofitable, trailing the broader US market's growth pace. The stock trades at a P/S of 1.9x, indicating a mixed valuation as it's priced below the industry average but above direct peers, raising concerns about its profitability outlook.
How many employees work at RxSight?
Revelio Labs reports that RxSight, Inc. currently has 439 employees, with a year-over-year growth rate of -1.3% as of December 2025. The article details historical employee counts, showing fluctuations in hiring and growth rates over the past few years. It also provides other workforce metrics like average salary, tenure, and active job postings, and mentions RxSight's business as an ophthalmic medical technology corporation.
Earnings call transcript: RxSight beats Q1 2026 forecasts, stock dips
RxSight (RXST) reported better-than-expected Q1 2026 earnings, posting an EPS of -$0.19 against a forecast of -$0.31, and revenue of $30.9 million, surpassing the $29.75 million estimate. Despite these positive financial results, the company's stock dipped 1.93% in aftermarket trading. The company maintained its full-year 2026 revenue guidance while focusing on strengthening its customer re-engagement programs and technological innovations for future growth.
RxSight, Inc. (RXST) Tops Q1 EPS by 12c
RxSight, Inc. (RXST) reported stronger-than-expected Q1 earnings, beating analyst estimates by $0.12 with an EPS of ($0.19). The company also surpassed revenue expectations, bringing in $30.9 million against a consensus estimate of $29.75 million. The stock is currently trading at $6.78, reflecting a 6.61% drop today.
RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates
RxSight, Inc. (RXST) reported a wider-than-expected Q1 loss of $0.19 per share, missing the Zacks Consensus Estimate of a $0.12 loss. Despite the earnings miss, the company surpassed revenue expectations, posting $30.89 million against an estimate of $29.68 million. The stock has underperformed the S&P 500 year-to-date and currently holds a Zacks Rank #4 (Sell), suggesting potential underperformance in the near future.
Eye-lens maker RxSight says sales slowed, but kept 2026 target
RxSight (NASDAQ: RXST) reported a 18.5% year-over-year revenue decline in Q1 2026 to $30.9 million, largely due to lower Light Delivery Device (LDD) unit volumes, but reiterated its full-year 2026 revenue guidance of $120–$135 million. The company's net loss widened to $15.9 million, yet it maintained a strong cash position of $217.9 million and announced positive clinical data and international expansion into New Zealand. Despite the sales slowdown, RxSight highlighted stabilizing business trends and ongoing commercial initiatives as it continues to invest in strategic growth.
RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook
RxSight, Inc. reported its first-quarter 2026 financial results, with sales of $30.9 million, an 18.5% decrease year-over-year, primarily due to lower Light Delivery Device (LDD) unit volumes. Despite the sales decrease, the company maintained its full-year 2026 sales and gross margin guidance, though operating expenses are expected to be at the higher end of the previous range due to strategic growth investments. Key highlights include advancements in its Light Adjustable Lens (LAL) technology and robust clinical data presented at the ASCRS meeting.
RxSight (NASDAQ: RXST) posts wider Q1 loss but keeps 2026 sales outlook
RxSight (NASDAQ: RXST) reported a wider net loss in Q1 2026, with sales declining 18.5% year-over-year to $30.9 million, primarily due to lower Light Delivery Device volumes. Despite this, the company affirmed its full-year 2026 revenue guidance of $120 to $135 million and gross margin of 70% to 72%, although operating expenses are now expected at the high end of their previous range. The company maintains a strong liquidity position with $217.9 million in cash and short-term investments.
Rxsight Inc expected to post a loss of 28 cents a share - Earnings Preview
Rxsight Inc (RXST) is projected to report a loss of 28 cents per share, according to an earnings preview. This information is provided by Refinitiv and is a concise analysis of the company's expected financial performance. The article is a brief look at the upcoming earnings for RXST.
Needham Maintains RxSight (RXST) Buy Recommendation
Needham has reiterated its Buy rating for RxSight (RXST). This indicates a continued positive outlook from the firm regarding the company's stock performance and potential.
RxSight (RXST) to Release Earnings on Wednesday
RxSight (NASDAQ:RXST) is scheduled to release its Q1 2026 earnings after market close on Wednesday, May 6, 2026. Analysts anticipate an EPS of ($0.12) and revenue of $29.73 million. RXST shares opened at $7.17, trading down about 1.6%, with analysts currently holding an average rating of "Reduce" and a consensus price target of $9.78.
Investors can watch RxSight's Bank of America fireside chat May 13
RxSight, Inc. (NASDAQ:RXST) announced it will participate in the Bank of America Healthcare Conference on May 13, 2026. Management will host a fireside chat at 3:00 p.m. Pacific Time, which will be accessible via a live and archived webcast on the company's investor relations website. This appearance is part of RxSight's ongoing engagement at major healthcare investor conferences.
RxSight, Inc. to Present at the Bank of America Healthcare Conference
RxSight, Inc. announced its participation in the Bank of America Healthcare Conference. Management is scheduled for a fireside chat on Wednesday, May 13, 2026, at 3:00 p.m. Pacific Time, with a live and archived webcast available on the company’s investor relations website. The company specializes in ophthalmic medical devices, particularly the RxSight Light Adjustable Lens system for customized vision after cataract surgery.
[ARS] RxSight, Inc. SEC Filing
This article announces an ARS SEC filing by RxSight, Inc. (RXST) on April 28, 2026. The filing is available as a PDF document directly from the SEC EDGAR source. The article also provides a brief overview of RXST's stock data, recent news, and other SEC filings.
RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6
RxSight, Inc. (NASDAQ: RXST) announced it will release its first-quarter 2026 financial results after the market close on Wednesday, May 6, 2026. A conference call to discuss these results will follow at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. The call details and a link to the webcast will be available on the company's investor relations website.
RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6
RxSight, Inc. announced it will report its first-quarter 2026 financial results after market close on Wednesday, May 6, 2026. A conference call will follow at 1:30 p.m. Pacific Time to discuss the results. The company specializes in ophthalmic medical devices, specifically the Light Adjustable Lens system for cataract surgery.
RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6
RxSight, Inc. announced that it will report its first-quarter 2026 financial results after market close on Wednesday, May 6, 2026. The company will host a conference call to discuss these results at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. RxSight is an ophthalmic medical device company known for its Light Adjustable Lens system, which allows customization of vision after cataract surgery.
RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6
RxSight, Inc. (NASDAQ: RXST) announced it will report its first-quarter 2026 financial results after market close on Wednesday, May 6, 2026. The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss these results, which will also be available for live broadcast and archived recording on its investor relations website. RxSight specializes in ophthalmic medical devices, providing adjustable intraocular lenses for cataract surgery.
RxSight (RXST) COO exercises stock options, now holding over 79,000 shares
RxSight, Inc. Chief Operating Officer Ilya Goldshleger exercised stock options to acquire 12,489 shares of common stock at $4.13 per share. Following this transaction, Goldshleger now directly holds 78,180 shares and indirectly 1,372 shares through his spouse, totaling over 79,000 shares. This exercise is described as a routine compensation-related equity event.
RXST: Premium lens adoption grows as utilization deepens and international expansion accelerates
RxSight, Inc. (RXST) is experiencing increased adoption of its premium ophthalmic solutions, driven by strong surgeon endorsement and deeper utilization within existing accounts. A key future growth area is international expansion, supported by regulatory progress and significant investments, while the Light Adjustable Lens (LAL) maintains strong pricing and margin stability.
Needham Maintains RxSight (RXST) Buy Recommendation
Needham has reiterated its Buy rating on RxSight (RXST). This indicates a continued positive outlook from the firm regarding the company's stock.
RxSight, Inc. (NASDAQ:RXST) Given Consensus Recommendation of "Reduce" by Analysts
Fifteen analysts have issued a consensus "Reduce" recommendation for RxSight, Inc. (NASDAQ:RXST), with an average 12-month price target of $9.78. Despite this, institutional investors hold 78.78% of the stock, with several large funds significantly increasing their positions recently. The company commercializes the Light Adjustable Lens for cataract and lens-replacement patients, and its shares opened at $6.83, well below their 12-month high of $16.74.
RxSight Highlights 300,000 Light Adjustable Lens Implant Milestone and Strong Scientific Presence at ASCRS 2026
RxSight, Inc. announced a significant milestone of over 300,000 Light Adjustable Lens (LAL) implants performed, in advance of the 2026 ASCRS annual meeting. The company will also have a strong scientific presence at the meeting with 35 presentations highlighting the versatility and impact of their adjustable intraocular lens technology. Additionally, RxSight is launching its "I Trust It with My Own Eyes" program, featuring ophthalmologists who have chosen the LAL for themselves.
RxSight Inc stock: 300,000 Lens Milestone Signals Growth Potential
RxSight Inc has reached a significant milestone with over 300,000 Light Adjustable Lens (LAL) implants worldwide, showcasing its leadership in customizable post-operative vision correction. This achievement, announced before ASCRS 2026, highlights growing surgeon adoption and strong clinical data for the LAL, which allows post-surgery fine-tuning of vision. For investors, this signals potential for revenue expansion in the premium intraocular lens market, driven by the increasing demand for advanced cataract surgery outcomes.
RxSight Reaches 300,000 Light Adjustable Lens Implant Milestone
RxSight, Inc. has announced a significant milestone of over 300,000 Light Adjustable Lens (LAL) implants performed, showcasing the growing adoption of its customizable vision correction technology. The company will also highlight the LAL system's clinical evidence and versatility with 35 presentations at the upcoming ASCRS 2026 annual meeting. This technology allows for post-cataract surgery vision optimization, redefining the standard of care with personalized and high-quality outcomes.
RxSight Highlights 300,000 Light Adjustable Lens Implant Milestone and Strong Scientific Presence at ASCRS 2026
RxSight, Inc. announced a significant milestone of over 300,000 Light Adjustable Lens (LAL) implants performed since its launch, ahead of the 2026 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting. The company will have a strong scientific presence at ASCRS 2026, featuring 35 presentations on LAL technology, highlighting its versatility and impact. RxSight is also launching its "I Trust It with My Own Eyes" program, featuring ophthalmologists who have chosen LAL for their own vision correction.
RxSight (Nasdaq:RXST) - Stock Analysis
This report provides a stock analysis for RxSight (Nasdaq:RXST), a medical technology company specializing in light adjustable intraocular lenses for cataract surgery. The company is currently undervalued according to analyst consensus and faces forecast earnings decline and unprofitability over the next three years. The analysis covers valuation, growth, financial health, past performance, and recent news, including strategic realignments and international expansion efforts.
RxSight Reaches 300,000 Light Adjustable Lens Implant Milestone
RxSight, Inc. has announced a significant milestone, having performed over 300,000 implants of its Light Adjustable Lens (LAL) since its launch. This customizable vision correction technology allows doctors to optimize vision after cataract surgery based on patient feedback. The company will also have a strong scientific presence at the ASCRS 2026 conference, with 35 presentations highlighting the clinical evidence and versatility of the LAL system.
RxSight reaches 300,000 Light Adjustable Lens implants since launch
RxSight announced that it has achieved 300,000 Light Adjustable Lens (LAL) implants since the product's launch, a significant milestone ahead of the 2026 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting. The LAL system is the only commercially available intraocular lens that allows post-cataract surgery vision adjustments, enabling customized patient outcomes. At ASCRS 2026, 35 scientific presentations will highlight clinical evidence supporting the technology, including data showing high accuracy and excellent vision results for patients.
RxSight Highlights 300,000 Light Adjustable Lens Implant Milestone and Strong Scientific Presence at ASCRS 2026
RxSight, Inc. announced a significant milestone of over 300,000 Light Adjustable Lens® (LAL®) implants performed since its launch, ahead of the ASCRS 2026 annual meeting. The company will have a strong scientific presence at the meeting, with 35 presentations highlighting the benefits of its adjustable intraocular lens technology. RxSight is also launching the "I Trust It with My Own Eyes" program, featuring ophthalmologists who have chosen the LAL for their own vision correction.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against RxSight, Inc. (RXST) And Encourages Shareholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential claims against RxSight, Inc. (RXST) concerning alleged corporate wrongdoing by its officers and/or directors. The firm encourages shareholders who purchased RxSight securities before November 7, 2024, and still hold them, to contact them to assist in the investigation. The representation of investors in such class actions is on a contingency fee basis.
RxSight reports 300,000 Light Adjustable Lens implants milestone
RxSight, Inc. announced that it has surpassed 300,000 Light Adjustable Lens (LAL) implants, which is their unique post-surgical adjustable intraocular lens technology. Despite a stock decline over the past year, the company reported strong revenue and gross profit margin, with analysts highlighting the stock as potentially undervalued. This milestone comes as 35 scientific presentations featuring LAL technology are set to be presented at the upcoming American Society of Cataract and Refractive Surgery annual meeting.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against RxSight, Inc. (RXST) and Encourages Shareholders to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has announced an investigation into potential corporate wrongdoing by RxSight, Inc. (NASDAQ:RXST) and certain of its officers and/or directors. The firm is encouraging shareholders who purchased RxSight securities prior to November 7, 2024, and continue to hold them, to join the investigation. The firm specializes in securities fraud class actions and shareholder derivative suits, and represents investors on a contingency fee basis.
RxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare Conference
RxSight, Inc. (NASDAQ: RXST) announced its participation in the 25th Annual Needham Virtual Healthcare Conference. Management is scheduled to present a fireside chat on Thursday, April 16, 2026, at 8:00 a.m. Pacific Time, with a webcast available on the company's investor relations website. RxSight specializes in ophthalmic medical devices, particularly the Light Adjustable Lens system for customized vision after cataract surgery.
RXST PE Ratio & Valuation, Is RXST Overvalued
Rxsight Inc (RXST) is currently categorized as undervalued, with a forward PS ratio of 1.90 compared to its five-year average of -17.26. Its fair price is estimated to be between $12.97 and $33.75, making it undervalued by 48.8% relative to its current price of $6.64. While the company's P/S ratio is slightly above the industry average, its negative revenue growth raises concerns about the sustainability of this premium.
RxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare Conference
RxSight, Inc. announced its participation in the 25th Annual Needham Virtual Healthcare Conference. Management is scheduled to hold a fireside chat on Thursday, April 16, 2026, at 8:00 a.m. Pacific Time, with a webcast available on the company's investor relations website. RxSight specializes in ophthalmic medical devices, including the Light Adjustable Lens system for customized vision after cataract surgery.
RxSight, Inc. (RXST) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against RxSight, Inc. (RXST) on behalf of investors who purchased securities prior to November 7, 2024, and continue to hold them. The investigation focuses on whether the company's officers and/or directors engaged in corporate wrongdoing. Investors are encouraged to contact the firm to learn more about the investigation and potentially assist.
RxSight to Participate in Annual Healthcare Conference
RxSight, Inc., an ophthalmic medical device company, announced its participation in the 25th Annual Needham Virtual Healthcare Conference. Management is scheduled to present and hold a fireside chat on April 16, 2026, at 8:00 a.m. Pacific Time, highlighting its innovative Light Adjustable Lens system. This participation aims to increase awareness of their technology among investors and industry peers.
RxSight management joins Needham virtual healthcare event Apr. 16
RxSight (NASDAQ: RXST) will participate in the 25th Annual Needham Virtual Healthcare Conference on April 16, 2026, with management hosting a fireside chat at 8:00 a.m. PT. While this event signals ongoing investor engagement, historical data suggests that conference participation announcements typically result in modest stock movements compared to financial updates or leadership changes. Investors are advised to focus on the company's execution against 2026 guidance and future operational milestones rather than this presentation for significant market impact.
